10:37 AM EDT, 03/25/2024 (MT Newswires) -- Tonix Pharmaceuticals Holding ( TNXP ) said Monday that the US Food and Drug Administration granted rare pediatric disease designation to TNX-2900 for the treatment of Prader-Willi syndrome in children and adolescents.

Prader-Willi syndrome is the leading genetic cause of life-threatening childhood obesity, the drugmaker said.

Tonix said it may be eligible to receive a transferable priority review voucher from the FDA if TNX-2900 is approved for marketing.

Price: 0.32, Change: -0.02, Percent Change: -7.23